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Abstract  
Introduction: Patients with oral squamous cell carcinoma currently experience a five year survival 
rate of approximately 60% with conventional surgical, chemotherapy and radiotherapy treatments. 
Magnetic hyperthermia offers an alternative treatment method by utilising the heating properties of 
magnetic nanoparticles to produce thermo-ablation of the tumour site when exposed to an 
alternating magnetic field. In this study we investigate in vitro if targeted magnetic hyperthermia 
offers a potential treatment for oral squamous cell carcinoma. Materials and methods: Magnetic 
iron oxide nanoparticles, with a biocompatible silica coating, were produced and conjugated with 
antibodies to target integrin ɲǀɴ ? ? Ă well-characterised oral squamous cell carcinoma biomarker. 
Utilising the heating properties of the magnetic nanoparticles we exposed them to an alternating 
magnetic field to produce thermo-ablation of tumour cells either negative for or over-expressing 
ŝŶƚĞŐƌŝŶɲǀɴ ?. Results: The cell surface biomarker, ɲǀɴ ? integrin, was upregulated in tissue biopsies 
from oral squamous cell carcinoma patients compared to normal tissue. Functionalisation of the 
silica coating with anti-ɲǀɴ ? ĂŶƚŝďŽĚŝĞƐ ĞŶĂďůĞĚ ĚŝƌĞĐƚ ƚĂƌŐĞƚŝŶŐ ŽĨthe nanoparticles to ɲǀɴ ?-
overexpressing cells and applying thermal therapy significantly increased killing of the targeted 
tumour cells compared to control cells. Conclusion: Combining antibody-targeting magnetic 
nanoparticles with thermal-ablation offers a promising therapy for the targeted treatment of oral 
squamous cell carcinoma.    
 
Keywords: Magnetic hyperthermia; nanoparticle; oral cancer; squamous cell carcinoma; integrin. 
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Introduction: 
Oral squamous cell carcinoma (OSCC) is the twelfth most common cancer worldwide, accounting for 
300,000 new cases every year (1). Despite advances in conventional treatment, including surgery 
and radio- or chemo- therapy, the prognosis for OSCC remains poor. Survival rates have not 
improved over the past few decades with currently only a 60% 5 year survival rate (2). As with other 
cancers, there is a need to develop novel targeted methods, to not only improve efficiency but to 
reduce unwanted off-target side-effects that often cause considerable reduction in the quality of life 
for the patient.  
 
An alternative potential cancer treatment, thermal ablation, involves applying heat (>50°C) to cause 
irreversible cell damage and necrosis of tumour cells (3, 4). A current challenge is delivering this heat 
selectively to only the site of the tumour and minimising damage of healthy tissue elsewhere. One 
potential solution is through the use of magnetic nanoparticles (MNP). These particles emit thermal 
energy when exposed to a rapidly alternating magnetic field in a process termed magnetic 
hyperthermia (5). This process allows the heating of cells that are closely localised to the MNP (6). In 
addition, the high surface area of MNP means they can be readily functionalised to enhance their 
biocompatibility or to immobilise drugs, or targeting agents such as antibodies. Functionalisation of 
the surface towards cancer cells has the potential to generate a more specific cell killing whilst 
simultaneously reducing off target effects on healthy tissue (7). 
 
Cancerous cells which display unique or highly upregulated biomarkers offer the opportunity to 
target treatments and diagnostics to the site they are needed, and bring about a reduction in off-
target side-effects (8). One such example is the heterodimeric transmeŵďƌĂŶĞ ƌĞĐĞƉƚŽƌ ɲǀɴ ? 
integrin. This integrin is expressed on epithelial cells (9) and is highly upregulated during wound 
healing, as well as on the leading edge of OSCC (10, 11) ?  dŚĞ ŝŶĐƌĞĂƐĞĚ ĞǆƉƌĞƐƐŝŽŶ ŽĨ ƚŚĞ ɲǀɴ ?
integrin in OSCC is associated with a poor prognosis and increased disease progression (12, 13). Cells 
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over-ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ɲǀɴ ? ŝŶƚĞŐƌŝŶ ƐŚŽǁ Ă ŵŽƌĞ ŝŶǀĂƐŝǀĞ ƉŚĞŶŽƚǇƉĞ ? ǁŝƚŚ ŝŶǀĂƐŝŽŶ ƚŚƌŽƵŐŚ ƚŚĞ
basement membrane and increased cell migration (14, 15). This is a direct resulƚŽĨɲǀɴ ?ďŝŶĚŝŶŐƚŽ
its ligand, causing the spread and development of cancer (9). The over-ĞǆƉƌĞƐƐŝŽŶŽĨɲǀɴ ?ŝŶƚĞŐƌŝŶŝŶ
tumours makes it an ideal molecule for the targeting of treatments in OSCC.  By functionalising with 
ĂŶɲǀɴ ?ĂŶƚŝďŽĚǇ ?ƚŚĞMNP, and therefore the hyperthermia treatment, can be localised to areas of 
tumour growth, offering a directed therapy with the potential for significantly reduced side-effects 
and minimised damage to healthy tissue.  
 
In this study we produced and characterised iron oxide MNP with a biocompatible silica shell, and 
conjugated them with an antibody against ɲǀɴ ? ?MNP were targeted specifically towards OSCC cells 
over-ĞǆƉƌĞƐƐŝŶŐɲǀɴ ?ĂŶĚĐĞůůsurvival determined after inducing magnetic hyperthermia. We found 
that specific targeting of the particles increased the effectiveness of the hyperthermic treatment by 
increasing cell death compared to non-conjugated MNP and hyperthermic treatment alone. 
 
Materials and Methods  
All materials used were purchased from Sigma-Aldrich Company Ltd (Dorset, UK), unless otherwise 
stated.  
Synthesis and coating of magnetic nanoparticles  
Iron oxide nanoparticles were synthesised using room temperature co-precipitation with a ferric to 
ferrous ration of 1:1 under a nitrogen atmosphere. MNP were dispersed in ethanol. Ultrapure water 
and ammonium hydroxide (30%) were added to the MNP, followed by tetraethyl orthosilicate under 
stirring for 5 hours. The MNPs were washed and dried under vacuum. MNP were dispersed in 
toluene (99.9%) before addition of ammonium hydroxide (30%) and (3-aminopropyl) triethoxysilane 
(APTES). After stirring for 1 hour at room temperature, the MNP were washed, before drying in 
vacuo. 
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Characterisation of magnetic nanoparticles  
MNP were characterised using x-ray diffraction (XRD) (Bruker D8 Powder Diffractometer Bruker 
Corporation Billerica, Massachusetts, USA) with data collected between 20° to 80° at 0.05° intervals. 
MNPs diameter and shell thickness was determined using an FEI Tecnai G2 Spirit transmission 
electron microscope (TEM) (FEI Company, Hillsboro, Oregon, USA), with image analysis in ImageJ.  
MNP heating was performed in a Magnetherm alternating field generator (NanoTherics, Keele, UK) 
operating at a recorded field strength of 9.7 mT (Nanoscience Laboratories, Keele, UK).  The coil was 
cooled via a recirculating water bath set at 20°C. Temperature increase during heating was recorded 
every 10 seconds with a fibre optic temperature probe. SAR and ILP values were calculated from the 
heating curve (18).  A superconducting quantum interference device (SQUID) was used to measure 
magnetic properties at 293 K. 
 
Antibody conjugation to the magnetic nanoparticles and ELISA. 
Anti-ɲǀɴ ? ŵŽƵƐĞ ŵŽnoclonal antibody (clone E7P6; Merck Millipore, Darmstadt, Germany) was 
conjugated to the MNP using glutaraldehyde cross linking.  MNP were dispersed in 2.5% 
glutaraldehyde solution (2 mg/ml) and sonicated for 1 hour at room temperature before washing 
using PBS. Anti-ɲǀɴ ?ŵŽƵƐĞŵď ? ? ?ʅŐ ?ŵůŝŶW^ ?ǁĂƐĂĚĚĞĚƚŽƚŚĞŐůƵƚĂƌĂůĚĞŚǇĚĞ-activated  
MNP and  allowed  to  conjugate  for  24  hours  at  4°C  on  a  roller mixer.   
Conjugation of antibody was confirmed using an ELISA.  The particles were blocked with Sigma Block 
prepared in PBS (Formedium, UK) with 0.05 % tween-20 (PBST). After one hour the MNP were 
supplemented with anti-mouse HRP conjugated antibody (New England Biolabs, Ipswich, 
Massachusetts, USA) at a ratio of 1:5000 and mixed for one hour, before transferring the MNP into 
fresh blocking buffer for five minutes, three times, with mixing. The particles were then magnetically 
collected and added to TMB reagent (Thermo Fisher, Waltham, Massachusetts, USA) for 30 minutes. 
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The colour change of the supernatant at 585 nm was recorded. MNP without the conjugated anti-
ɲǀɴ ?ĂŶƚŝďŽĚǇǁĞƌĞƚƌĞĂƚĞĚŝŶƚŚĞƐĂŵĞǁĂǇĨŽƌĐŽŵƉĂƌŝƐŽŶ ?
Cell culture 
Two OSCC cell lines with defined integrin expression were selected; VB6 (over-expressing high levels 
ŽĨɲǀɴ ? ? ?ŬŝŶĚůǇƉƌŽǀŝĚĞĚďǇƌ^tŚĂǁĞůů ?ĂŶĚŝƚƐƉĂƌĞŶƚĐĞůůůŝŶĞ, ? ? ? ?ŶĞŐĂƚŝǀĞĨŽƌƚŚĞɲǀĂŶĚɴ ?
integrin subunits), (Health Protection Agency Culture Collections, Salisbury, UK)(16) and cultured as 
previously described (14). Briefly, cells were cultured in flavin and adenine-enriched medium 
 ?'ƌĞĞŶ ?Ɛ ŵĞĚŝum ? PƵůďĞĐĐŽ ?Ɛ DŽĚŝĨŝĞĚĂŐůĞ ?Ɛ DĞĚŝƵŵ  ?DD ?ĂŶĚ ,Ăŵ ?Ɛ & ? ? ŵĞĚŝƵŵ ŝŶĂ  ? P ?
(v ?ǀ ? ƌĂƚŝŽ ƐƵƉƉůĞŵĞŶƚĞĚ ǁŝƚŚ  ? ?A?  ?ǀ ?ǀ ? ĨŽĞƚĂů ĐĂůĨ ƐĞƌƵŵ  ?&^ ? ?  ? ? ? ʅD ĐŚŽůĞƌĂ ƚŽǆŝŶ ?  ? ? ŶŐ ?ŵů
ĞƉŝĚĞƌŵĂů ŐƌŽǁƚŚ ĨĂĐƚŽƌ ?  ? ? ? ʅŐ ?ŵů ŚǇĚƌŽĐŽƌƚŝƐŽŶĞ ?  ? ? ? ?ŵD ĂĚĞŶŝŶĞ ?  ? ʅŐ ?ŵů ŝŶƐƵůŝŶ ?  ? ʅŐ ŵů
ƚƌĂŶƐĨĞƌƌŝŶ ?  ? ŵD ŐůƵƚĂŵŝŶĞ ?  ? ? ? ʅD ƚƌŝŝŽĚŽƚŚǇƌŽŶŝŶĞ ?  ? ? ? ? ? ʅŐ ?ŵů ĂŵƉhotericin B, 100 IU/ml 
penicillin and 100 ʅŐ ?ŵůƐƚƌĞƉƚŽŵǇĐŝŶĂƚ ? ? ? ? ?A?K2 (17).  
Immunohistochemistry 
Paraffin-embedded tissue sections (5 µm) were prepared from normal oral mucosa and archival 
HNSCC biopsies in accordance with the Sheffield Research Ethics Committee approval (Ref: 
07/H1309/105). Sections were dewaxed, rehydrated and endogenous peroxidase neutralised with 3% 
hydrogen peroxide for 20 minutes. Following proteinase K antigen retrieval samples were blocked 
using protein-free blocking solution (Dako, Copenhagen, Denmark) for 20 minutes at room 
temperature and then 5 µg/ml mouse monoclonal anti-ɲǀɴ ? ĂŶƚŝďŽĚǇ  ?clone E7P6) applied for 1 
hour at room temperature. Secondary antibody and avidin-biotin complex (ABC) provided with 
Vectastain Elite ABC kit (Vector Labs, Peterborough, UK) were then used in accordance with the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?&ŝŶĂůůǇ ? ? ?-diaminobenzidine tetrahydrochloride (DAB) (VectorLabs) was 
used to visualise peroxidase activity and the sections were counterstained with haematoxylin, 
dehydrated and mounted in DPX. Images were taken using an Olympus BX51 microscope and Colour 
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view IIIu camera with associated Cell^D software (Olympus Soft Imaging Solutions, GmbH, Munster, 
Germany). 
Flow cytometry 
Cells were removed from tissue culture flasks non-enzymatically, pelleted, and re-suspended in cold 
PBS supplemented with 1% BSA and 0.1% sodium azide (FACS buffer). Cells (1 X 10
6
) were incubated 
with 10 µg/ml anti-ɲǀɴ ?ŵŽƵƐĞŵŽŶŽĐůŽŶĂůĂŶƚŝďŽĚǇ ?ĐůŽŶĞ ? ? ?' ? ?Žƌ/Ő'ŝƐŽƚǇƉĞĐŽŶƚƌŽů ? Following 
washes with FACS buffer, cells were incubated with AlexaFlour 488-conjugated anti-mouse 
secondary antibody (Invitrogen, Paisley, UK) for 30 minutes on ice in the dark, then washed twice 
and re-suspended with FACS buffer. Flow cytometry was performed using a FACSCalibur (Becton 
Dickinson, San Jose, CA, USA); propidium iodide was used to gate out non-viable cells and data were 
analysed using FlowJo® software (FlowJo, LLC, USA). 
 
Treatment of OSCC cells with silica magnetic nanoparticles  
VB6 cells were seeded onto a 35 mm cell culture plate at a density of 1.5 X 10
5
 cells and incubated 
ĨŽƌ  ? ?ŚŽƵƌƐďĞĨŽƌĞĚŽƐŝŶŐǁŝƚŚ  ? ? ?ŵŐ ?ŵůŽĨɲǀɴ ?-MNP (ɲMNP) or vehicle control (uMNP). Cells 
were exposed to an alternating magnetic field (9.7 mT) for 10 minutes, along with appropriate 
controls. Cells were re-incubated for 24 and 48 hours after treatment before being analysed for cell 
viability using an alamarBlue® assay (Thermo Fisher, Waltham, Massachusetts, USA).  
Analysis of cells after magnetic hyperthermia treatment 
Cell metabolism was measured by adding alamarBlue® solution to cells  ? ? P ? ? ŝŶ 'ƌĞĞŶ ?Ɛ DĞĚŝƵŵ ?
ĂŶĚ ŝŶĐƵďĂƚŝŶŐ ĨŽƌ  ? ŚŽƵƌƐ Ăƚ  ? ?ȗ ?  ? A? K2 before removing the reagent and subjecting it to 
centrifugation at 1800 x g for 5 minutes. The alamarBlue® solution was transferred into a 96 well 
plate and the fluorescence measured using a spectrophotometer at a wavelength of 585 nm. After 
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removal of the alamarBlue® solution, the cell plates were washed with PBS and fresh medium added 
before being re-ŝŶĐƵďĂƚĞĚĂƚ ? ?ȗ ? ?A?K2. 
Statistics 
Data are presented as mean values ± standard deviation (SD) of three independent experiments 
(n=3), unless otherwise stated. Statistical comparisons were performed using GraphPad Prism v7.00 
(GraphPad Software, La Jolla, CA, USA). Group-wise comparisons were carried out using one-way 
independent analysis of variance (ANOVA) with TukeǇ ?ƐŵƵůƚŝƉůĞĐŽŵƉĂƌŝƐŽŶƐƚĞƐƚ ?and differences 
considered significant when p<0.05. 
 
Results  
Production and characterisation of magnetic nanoparticles 
MNP or iron oxide were synthesised using a simple room temperature coprecipitation of ferrous and 
ferric iron in sodium hydroxide. The solution of iron salts was added to a large excess of sodium 
hydroxide via a controlled dropwise addition. The resulting black precipitate was magnetically 
recovered, before coating with an amine terminated silica shell using conventional sol gel chemistry. 
The presence of surface exposed amine groups allows for convenient functionalisation later.  The 
size and morphology of the MNP were analysed using TEM both before and after the coating step, 
allowing measurement of both the size of the iron oxide core and the thickness of the silica shell. 
The mean diameter of the uncoated MNP was found to be 8 + 6 nm (Figure 1, A), and after coating, a 
uniform 6 nm thick layer of lower electron density was visible surrounding the MNP (Figure 1, B, C). 
The TEM images show some nanoscale clustering of particles upon drying onto the sample grid. X-
ray diffraction (XRD) analysis of the MNP produced characteristic peaks consistent with the expected 
reflections for magnetite (ICDD card # 88-0866) (Figure 1, D), although the presence of the closely 
related iron oxide maghemite cannot be fully excluded. Magnetic hysteresis experiments of silica 
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coated MNP revealed a coercivity of 13 Oe (Figure 1,E) and a saturation magnetisation of 56 emu/g.  
Due to their size and distribution it is likely that the sample comprises a mixed population of 
superparamagnetic and single domain ferrimagnetic particles.  
 
We therefore exposed an 8 mg/ml aqueous suspension of the coated MNP to a rapidly alternating 
magnetic field (frequency of 174 kHz, magnetic field strength of 97 Oe) and recorded the heat rise of 
the solution using a fibre optic temperature probe. The calculated specific absorption rate (SAR) 
from the heating curve was 21.75 W/g with an intrinsic loss parameter (ILP) of 2.09 nHm
2
/k (Figure 1, 
F) (18).  We wanted to exploit this hyperthermic potential for OSCC cell killing and to enhance any 
cell killing effects by specifically targeting the particles to OSCC cells.  
 
K^ŽǀĞƌĞǆƉƌĞƐƐƚŚĞŝŶƚĞŐƌŝŶɲǀɴ ? 
Using immunohistochemistry, we confirmed as a suitable biomarker to differentiate between 
ŶŽƌŵĂů ĂŶĚ ĐĂŶĐĞƌŽƵƐ ƚŝƐƐƵĞ ? WĂƚŝĞŶƚ ĚĞƌŝǀĞĚ ŶŽƌŵĂů ŽƌĂů ŵƵĐŽƐĂ ĂŶĚ K^ ƐƚĂŝŶĞĚ ĨŽƌ ɲǀɴ ?
ŝŶƚĞŐƌŝŶƌĞǀĞĂůĞĚĞǆƉƌĞƐƐŝŽŶŽĨɲǀɴ ?ĐŽŶĨŝŶĞĚƚŽƚŚĞďĂƐĂůŬĞƌĂƚŝŶŽĐǇƚĞƐŝŶƚŚĞŶŽƌŵĂůŽƌĂůŵƵĐŽƐĂ ?
but a high level of expression was present throughout the cancerous tissue (Figure 2, A-B), 
confirming higher expression in cancerous tissue. A panel of OSCC cell lines were screened by flow 
ĐǇƚŽŵĞƚƌǇĨŽƌƉŽƐŝƚŝǀĞĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞɲǀɴ ?ŝŶƚĞŐƌŝŶ ?ĚĂƚĂŶŽƚƐŚŽǁŶ ? ?tĞƐĞůĞĐƚĞĚ H357 and VB6 
cell lines for in vitro testing of our functionalised MNP experiments due to their respective negative 
and positive expression of the integrin (Figure 2, C). 
 
MNP functionalisation with anti-ɲǀɴ ?ĂŶƚŝďŽĚǇ 
The MNP were functionalised with anti-ɲǀɴ ? ĂŶƚŝďŽĚǇ ? ǀŝĂ ŐůƵƚĂƌĂůĚĞŚǇĚĞ ĐƌŽƐƐůŝŶŬŝŶŐ ŽĨ ƚŚĞ ĨƌĞĞ
amine groups of the antibody with the amine terminated surface of the silica shell. This method 
provides a stable, covalent linkage between the targeting molecule and the MNP. Using a modified 
magnetic particle-based ELISA, the antibody functionalised particles provided a positive absorbance 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
reading, significantly higher compared to non-antibody conjugated controls (p=0.0009) and 
detection reagent alone (p=0.0024) (Figure 3), indicating successful attachment.  
 
Anti-ɲǀɴ ?-ĐŽŶũƵŐĂƚĞĚDEWƚĂƌŐĞƚĞĚĐǇƚŽƚŽǆŝƚǇŝŶɲǀɴ ?ŽǀĞƌĞǆƉƌĞƐƐŝŶŐĐĞůůƐ 
Anti-ɲǀɴ ?-ĐŽŶũƵŐĂƚĞĚDEW ?ɲDEW ?ĂŶĚƵŶĐŽŶũƵŐĂƚĞĚDEW ?ƵDEW ?ǁĞƌĞŝŶĐƵďĂƚĞĚǁŝƚŚďŽƚŚƚŚĞ
ɲǀɴ ?-ŶĞŐĂƚŝǀĞ  ?, ? ? ? ? ĂŶĚ ɲǀɴ ?-positive (VB6) cell lines for 30 minutes and exposed to an 
alternating magnetic field (AMF) for a single 10 minute treatment to induce magnetic hyperthermia 
(MHT). Cell survival was measured at 24 and 48 hours post treatment using an alamarBlue® assay 
(Figure 4).  After 24 hours no effect on cell death was seen in the H357 cells treated with either 
ɲDEWŽƌƵDEWŝŶboth the hyperthermia or no hyperthermia groups (Figure 4, A-B). At 48 there is a 
ƐŵĂůů ĞĨĨĞĐƚ ŽŶ ďŽƚŚ ƚŚĞ ǀŝĂďŝůŝƚǇ ŽĨ ɲDEW ĂŶĚ ƵDEW ƚƌĞĂƚŵĞŶƚ ŐƌŽƵƉƐ ƚŚĂƚ ƵŶĚĞƌǁĞŶƚ
hyperthermia but there is no significant difference between the targeted and untargeted treatment 
groups (Figure 4, C-D). In contrast tŚĞsɴ ?ĐĞůůůŝŶĞƐƐŚŽǁĞĚŝŶĐƌĞĂƐĞĚƐƵƐĐĞƉƚŝďŝůŝƚǇƚŽƚŚĞƉƌĞƐĞŶĐĞ
ŽĨďŽƚŚɲDEWŽƌƵDEWǁŝƚŚŽƵƚŚǇƉĞƌƚŚĞƌŵŝĂĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞ, ? ? ?ĐĞůů ůŝŶĞďƵƚ ŝŶ ƚŚĞ ɲDEW
targeted population undergoing hyperthermia there was a greater, more significant, decrease to 
below 50% of the control at 24 hours and below 25 % at 48 hours. 
 
Discussion 
More effective treatments against OSCC are urgently needed to improve outcomes and survival 
rates for patients. We have therefore, for the first time, brought together the emerging field of 
magnetic hyperthermia for cell heating and destruction, with an under exploited biomarker for OSCC, 
resulting in a promising new targeted treatment approach.  
Iron oxide nanoparticles have been the subject of many studies into their use as magnetic 
hyperthermia agents, due to their intrinsic magnetic properties and biocompatibility (19). In 
particular, the iron oxide magnetite has favourable magnetic properties for hyperthermia treatment, 
but this is dependent on the size and shape of the particles used. We wanted to produce magnetite 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
nanoparticles with suitable characteristics to allow them to be readily taken up into cells, and, 
crucially, still possess sufficient heating potential for cell killing.   Previous studies which have 
investigated cellular uptake of iron oxide nanoparticles, suggest that the smaller the particles the 
higher the level of uptake (19) . This clearly needs to be balanced against the heating potential, 
whereby larger particles generally display greater levels of magnetically induced heating (20). To this 
end, we employed a synthesis of magnetite using a simple room temperature co-precipitation of 
Fe
2+
/Fe
3+
 ions.  The TEM particle sizing, powder XRD pattern, and coercivity are all consistent with 
small 8-12 nm magnetite nanoparticles. The measured SAR value matches that observed for similarly 
sized magnetite nanoparticles which achieve hyperthermia via Néel and Brownian modes (5).  
We encapsulated the particles within an amine terminated silica shell in order to preserve the 
magnetite core from oxidation, minimise any unwanted cytotoxicity, and provide a functionalised 
surface for convenient conjugation to antibodies (21). In addition, silica coating has previously been 
shown to improve cellular uptake of iron oxide nanoparticles (22).    
 
In agreement with others, tŚĞɲǀɴ ? ŝŶƚĞŐƌŝŶ ŝƐŚŝŐŚůǇĞǆƉƌĞƐƐĞĚby OSCC tumour cells, making it a 
suitable target molecule for antibody-directed therapy (23). Being able to specifically target such 
MNP to cancer cells, allows for efficient heating and destruction of tumour cells whilst minimising 
effects on healthy tissue. We have demonstrated this in vitro, where MNP displaying an anti-ɲǀɴ ?
antibody resulted in the death of 85% of VB6 cells with only a single 10 minute exposure to an 
alternating magnetic field. This is in contrast to only a 20% reduction in cell viability ĨŽƌ ɲǀɴ ?-
negative (H357) cells exposed to the same regime.  A further reduction in cell viability, for cultures 
exposed to both MNP and the alternating magnetic field, in both cell lines 48 hours after treatment 
compared to 24 hours was also observed. dŚĞ ĂĚĚŝƚŝŽŶ ŽĨ ɲDEW ƚŽ ďŽƚŚ ĐĞůů ůŝŶĞƐ ƌĞǀĞĂůƐ Ă
significant reduction in cell viability in VB6 experiments, both at 24 and 48 hours post addition, with 
negligible effects observed in the H357 cells which display lower levels of the target biomarker. This 
suggests that the presence of the antibody modulates MNP interaction with the cells, and negatively 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
imƉĂĐƚƐ ĐĞůůƐ ŽǀĞƌ ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ɲǀɴ ? ƌĞĐĞƉƚŽƌ ? KŶĐĞ ĐŽƵƉůĞĚ ǁŝƚŚ D,d ƚŚĞ s ? ĐĞůůƐ ƐŚŽǁ
ĚĞĐƌĞĂƐĞĚ ĐĞůů ƐƵƌǀŝǀĂů ǁŝƚŚ ƚŚĞ ɲDEW ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƵDEW Ăƚ ďŽƚŚ  ? ? ĂŶĚ  ? ? ŚŽƵƌƐ ƉŽƐƚ D,d
treatment. In comparison, H357 cells exposed to the same regime showed no difference in 
ĞĨĨĞĐƚŝǀĞŶĞƐƐ ďĞƚǁĞĞŶ ƚŚĞ ƵDEW ĂŶĚ ɲDEW ? KŶůǇ s ? ĐĞůůƐ ? ƚƌĞĂƚĞĚ ǁŝƚŚ ƚŚĞ ɲsɴ ? ĂŶƚŝďŽĚǇ-
targeted therapy, produced a significant drop in cell viability at both 24 (p<0.0001) and 48 (p<0.0001) 
ŚŽƵƌƐ ?/ŶƚĞƌĞƐƚŝŶŐůǇƚŚĞĐĞůůƐƵƌǀŝǀĂůŝŶɲDEWƚƌĞĂƚĞĚ VB6 cells continues to fall between 24 and 48 
hours after MHT. We surmise that the cells may have undergone their first complete cell cycle during 
the 24 to 48-hour time points post MHT, which suggests that apoptosis may be occurring as the cells 
undergo division, perhaps triggered by cellular damage that is not immediately lethal. A similar 
effect is observed in H357 cells where MHT exposed cells also show a decrease in survival between 
24 and 48 hours post treatment. At 48 hours post treatment, both cell lines exposed to uMNP and 
D,d ?ĂƐǁĞůůĂƐƚŚĞɲDEWŝŶƚŚĞ, ? ? ?ĞǆƉĞƌŝŵĞŶƚ ?ƉƌŽĚƵĐĞĚǀ ƌǇƐŝŵŝůĂƌ ůĞǀĞůƐŽĨĐĞůůǀŝĂďŝůŝƚǇ ?/Ŷ
these cases, we would anticipate that the MNP are behaving in an untargeted fashion and represent 
the background level of cell killing produced from non-specific, residual levels of MNP when MHT is 
applied. This also confirms that the presence of both the antibody and over expressed receptor are 
required in order to access higher levels of cell killing.    
 
In summary, we have synthesised and tested a MHT agent which is targeted towards VB6 cells 
associated with OSCC. Our results indicate efficient and significant cell killing when exposed to an 
alternating magnetic field, and only when the VB6 antibody is adequately paired with its cognate 
antigen. This promising in vitro study indicates that through careful pairing of antigen, antibody and 
nanoparticle, the killing potential of OSCC by magnetic hyperthemia can be significantly enhanced. 
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Figure Legends  
 
Figure 1: Magnetic nanoparticle characterisation. (A) TEM images of synthesised MNP and (B) silica 
coated MNP. (C) Frequency distribution of MNP. (D) XRD of MNP with peaks corresponding to the 
iron oxide magnetite. (E) SQUID magnetic hysteresis measurements of coated MNP. (F) Temperature 
increase of MNP when exposed to an alternating magnetic field. Scale bar = 40 nm.  
 
Figure 2: Biomarker selection. Immunohistochemical analysis of (A) normal and (B) OSCC reveal that 
ɲǀɴ ? ŝŶƚĞŐƌŝŶ ŝƐ ĞǆƉƌĞƐƐĞĚ ĞǆĐůƵƐŝǀĞůǇ ŽŶ ďĂƐĂů ŬĞƌĂƚŝŶŽĐǇƚĞƐ ŝŶ ŶŽƌŵĂů ƚŝƐƐƵĞ ǁŚŝůƐƚ ĞǆƉƌĞƐƐŝŽŶ ŝƐ
observed in all epithelial cells in OSCC. (C) Flow cytometry analysis of the ɲvɴ6 integrin expression 
on H357 and the overexpressing VB6 cell line demonstrates that H357 are negative for the integrin 
whilst VB6 show a positive expression on 65% of the cell population (n=3). Scale bar = 50 µm. 
 
Figure 3: Antibody conjugation. An enzyme-linked immunosorbent assay comparing MNP before 
and after anti-ɲvɴ6 integrin conjugation revealed antibody stably bound to the surface of the MNP 
(n=3). **denotes a statistically significant difference of p<0.01 and  *** p<0.001.   
 
Figure 4: Targeted magnetic nanoparticle hyperthermia treatment. H357 and VB6 cell monolayers 
were exposed to either anti-ɲvɴ6 conjugated MNP, un-conjugated MNP or no particles for 1 hour 
before exposure to an alternating magnetic field for 10 minutes. Cells were cultured for a further 24 
and 48 hours and cell survival measured using alamarBlue® (n=3). **denotes a statistically significant 
difference of p<0.01,  *** p<0.001 and **** p<0.0001.    
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